MANKIND - Trading Opportunity in the short termTF: daily
CMP: 2330
Observation:
Price is bouncing from the breakout Retest zone
Price is taking support at the 200 DEMA 50 DEMA confluence zone
Price made a doji at the support and reversal confirmation is in play.
Positional players can enter now and hold. One can wait for another pullback and
Compare with Mankind Pharma Ltd.
46.35 INR
19.13 B INR
142.78 B INR
112.91 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Profile
Sector
Industry
CEO
Sheetal Arora
Website
Headquarters
New Delhi
Founded
1986
IPO date
May 9, 2023
ISIN
INE634S01028
FIGI
BBG01G9WXGC8
Identifiers
ISIN INE634S01028
Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. It offers products under the brands of Nurokind, Telmikind, Manforce, Unwanted, Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Prega News, Dydroboon, Cefakind, Monticope, and Caldikind. The company was founded by Ramesh Chand Juneja in 1986 and is headquartered in New Delhi, India.
MANKIND PHARMA – SWING TO POSITIONAL TRADE SETUP LOADING .......✅ Accumulation Near Key Support
Price is holding the ₹2,300–₹2,340 demand zone.
Previous resistance is attempting to become support.
✅ Multi-Month Trendline Breakout
Long-term descending trendline has been broken.
Signals potential trend reversal after a prolonged correction.
✅ Volume Confirms I
MANKIND - A must consider script in the Pharma spaceCMP: 2520
TF: Daily
Most of the scripts had a great run since covid and they were multiplied by 5-8x since covid.
Since this script listed only in 2024, and didnt move much, and also in the pharma space, i believe that this script has a great potential compared to every other stock in the pharma s
Review and plan for 20th May 2026 Nifty future and banknifty future analysis and intraday plan.
This video is for information/education purpose only. you are 100% responsible for any actions you take by reading/viewing this post.
please consult your financial advisor before taking any action.
----Vinaykumar hiremath, CMT
Amazing INVESTMENT on WEEKLY Timeframe - MANKINDCheckout an amazing breakout happened in the stock in Weekly timeframe, macroscopically seen in Daily timeframe. Having a great favor that the stock might be bullish expecting a staggering returns of minimum 25% TGT. IMPORTANT BREAKOUT LEVELS ARE ALWAYS RESPECTED!
NOTE for learners: Place the break
Chart – MANKIND (Educational View)Sharing this chart for educational purposes and market study.
This is not a buy/sell recommendation. It’s a structured view of current price behavior around key levels.
Focus areas on the chart:
• Market structure
• Key support & resistance zones
• Reaction zones where price is responding
• Possib
MANKIND Hi,
Price traded in channel and now at lower end of channel so possiblity that it will be moves upper side. Let's see what happens
This idea is for Educational purpose and paper trading only. Please consult your financial advisor before investing or making any position. Facts or Data given above
MANKIND PHARMA- MULTIPLE SUPPORTS & RESISTANCESI have drawn support and resistance lines. it may be following the trend lines. May not be as well... need more time to see if the trend lines are being supported by the stock. As of now, volumes are missing and stock has held its price. Earnings on 28th August. Stock likely to remain range bound. M
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
7.961% YTM
Maturity dateNov 16, 2027
Coupon7.97% (Fixed)
7.915% YTM
Maturity dateOct 16, 2026
Coupon7.99% (Fixed)
See all MANKIND bonds
Frequently asked questions
The current price of MANKIND is 2,525.10 INR — it has decreased by −0.27% in the past 24 hours. Watch Mankind Pharma Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange Mankind Pharma Ltd. stocks are traded under the ticker MANKIND.
MANKIND stock has risen by 1.05% compared to the previous week, the month change is a 5.26% rise, over the last year Mankind Pharma Ltd. has showed a 0.20% increase.
We've gathered analysts' opinions on Mankind Pharma Ltd. future price: according to them, MANKIND price has a max estimate of 3,000.00 INR and a min estimate of 2,057.00 INR. Watch MANKIND chart and read a more detailed Mankind Pharma Ltd. stock forecast: see what analysts think of Mankind Pharma Ltd. and suggest that you do with its stocks.
MANKIND reached its all-time high on Dec 23, 2024 with the price of 3,054.80 INR, and its all-time low was 1,242.00 INR and was reached on May 22, 2023. View more price dynamics on MANKIND chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MANKIND stock is 2.45% volatile and has beta coefficient of 0.44. Track Mankind Pharma Ltd. stock price on the chart and check out the list of the most volatile stocks — is Mankind Pharma Ltd. there?
Today Mankind Pharma Ltd. has the market capitalization of 1.04 T, it has increased by 1.19% over the last week.
Yes, you can track Mankind Pharma Ltd. financials in yearly and quarterly reports right on TradingView.
Mankind Pharma Ltd. is going to release the next earnings report on Aug 5, 2026. Keep track of upcoming events with our Earnings Calendar.
MANKIND earnings for the last quarter are 14.00 INR per share, whereas the estimation was 10.15 INR resulting in a 37.93% surprise. The estimated earnings for the next quarter are 13.12 INR per share. See more details about Mankind Pharma Ltd. earnings.
Mankind Pharma Ltd. revenue for the last quarter amounts to 34.43 B INR, despite the estimated figure of 33.86 B INR. In the next quarter, revenue is expected to reach 39.79 B INR.
MANKIND net income for the last quarter is 5.54 B INR, while the quarter before that showed 4.09 B INR of net income which accounts for 0.00% change. Track more Mankind Pharma Ltd. financial stats to get the full picture.
Yes, MANKIND dividends are paid semi-annually. The last dividend per share was 1.00 INR. As of today, Dividend Yield (TTM)% is 0.04%. Tracking Mankind Pharma Ltd. dividends might help you take more informed decisions.
As of Jul 12, 2026, the company has 27 K employees. See our rating of the largest employees — is Mankind Pharma Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Mankind Pharma Ltd. EBITDA is 36.17 B INR, and current EBITDA margin is 25.62%. See more stats in Mankind Pharma Ltd. financial statements.
Like other stocks, MANKIND shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Mankind Pharma Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Mankind Pharma Ltd. technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Mankind Pharma Ltd. stock shows the strong buy signal. See more of Mankind Pharma Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.









